Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma
一项随机、双盲 II 期临床试验的结果显示，在接受切除手术的高危黑色素瘤患者中，NY-ESO-1 疫苗联合 ISCOMATRIX 佐剂与单独使用 ISCOMATRIX 佐剂的疗效存在差异。
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2019-000410
Cebon, Jonathan S; Gore, Martin; Thompson, John F; Davis, Ian D; McArthur, Grant A; Walpole, Euan; Smithers, Mark; Cerundolo, Vincenzo; Dunbar, P Rod; MacGregor, Duncan; Fisher, Cyril; Millward, Michael; Nathan, Paul; Findlay, Michael P N; Hersey, Peter; Evans, T R Jeffry; Ottensmeier, Christian Hermann; Marsden, Jeremy; Dalgleish, Angus G; Corrie, Pippa G; Maria, Marples; Brimble, Margaret; Williams, Geoff; Winkler, Sintia; Jackson, Heather M; Endo-Munoz, Liliana; Tutuka, Candani S A; Venhaus, Ralph; Old, Lloyd J; Haack, Dennis; Maraskovsky, Eugene; Behren, Andreas; Chen, Weisan
